Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02558595 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

A Phase 2 study, sponsored by University of Kansas Medical Center.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target

NCT02558595 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02558595, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Niacinamide

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2015-09-22
Est. Completion 2017-12-18
Phase Phase 2

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT02558595

The ClinicalTrials.gov registry entry for NCT02558595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02558595 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02558595 about?

NCT02558595 is a clinical study titled "Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)". The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

What is the current status of trial NCT02558595?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-09-22. Estimated completion is 2017-12-18.

What interventions are being tested in trial NCT02558595?

The interventions under investigation include: Placebo (OTHER), Niacinamide (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02558595?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.